Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancyOliver Groß, Manfred Weber, Bodo B. Beck et al.|Kidney International|2011Cited by 361
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndromeOliver Groß, Markus Feldkoetter, Burkhard Tönshoff et al.|Kidney International|2020Cited by 151